An immunogenic cell death-related lncRNA signature correlates with prognosis and tumor immune microenvironment in bladder cancer.

Publisher: Nature Publishing Group Country of Publication: England NLM ID: 101563288 Publication Model: Electronic Cited Medium: Internet ISSN: 2045-2322 (Electronic) Linking ISSN: 20452322 NLM ISO Abbreviation: Sci Rep Subsets: MEDLINE

Original Publication: London : Nature Publishing Group, copyright 2011-

Urinary Bladder Neoplasms*/genetics ; Urinary Bladder Neoplasms*/immunology ; Urinary Bladder Neoplasms*/pathology ; Urinary Bladder Neoplasms*/mortality ; RNA, Long Noncoding*/genetics ; Tumor Microenvironment*/immunology ; Tumor Microenvironment*/genetics ; Gene Expression Regulation, Neoplastic* ; Immunogenic Cell Death*; Humans ; Prognosis ; Female ; Male ; Biomarkers, Tumor/genetics ; Gene Expression Profiling ; Middle Aged ; ROC Curve ; Aged ; Kaplan-Meier Estimate

Immunogenic cell death (ICD) is a newly discovered form of cellular demise that triggers adaptive immune responses mediated by T cells. However, the immunogenic cell death-related lncRNAs (ICDRLs) involved in bladder cancer (BC) development and progression remain to be further elucidated. Molecular profiling data and clinicopathological information for BC patients were obtained from TCGA, and the ICDRGs list was obtained from published literature. For the identification of ICDRLs, Pearson co-expression analysis was performed, and a prognostic signature based on 13 ICDRLs was constructed by univariate assays and LASSO assays. Herein, an ICDRLSig consisting of 13 ICDRLs was constructed. KM curves and ROC curves demonstrated that the constructed signature in the TCGA training, testing, entire and external sets have good predictive performance. Multivariate assays illuminated that the signature is an independent predictor for BC patients' OS, exhibiting greater predictive power for the survival than traditional clinicopathological features. Additionally, patients in the high-ICDRLSig risk subgroup had more abundant immune infiltration, higher immune checkpoint gene expression, lower TMB and poorer response to immunotherapy. We have developed a novel ICDRLSig that can be exploited for survival prediction and provide a reference for further individualized treatment.
(© 2024. The Author(s).)

J Immunother Cancer. 2020 Mar;8(1):. (PMID: 32209603)
J Immunother Cancer. 2018 Jun 22;6(1):63. (PMID: 29929551)
Genome Res. 2018 Nov;28(11):1747-1756. (PMID: 30341162)
Cell Death Dis. 2020 Nov 26;11(11):1013. (PMID: 33243969)
JAMA Oncol. 2017 Nov 01;3(11):1529-1537. (PMID: 28687838)
Biomed Pharmacother. 2020 Sep;129:110393. (PMID: 32559616)
Onco Targets Ther. 2018 Oct 04;11:6415-6424. (PMID: 30323619)
PLoS One. 2014 Sep 17;9(9):e107468. (PMID: 25229481)
Cancer Res. 2017 Aug 1;77(15):3965-3981. (PMID: 28701486)
Cell Rep. 2017 Jan 3;18(1):248-262. (PMID: 28052254)
BMC Bioinformatics. 2013 Jan 16;14:7. (PMID: 23323831)
Acta Med Acad. 2021 Apr;50(1):143-156. (PMID: 34075770)
Nat Commun. 2013;4:2612. (PMID: 24113773)
Cell Stress Chaperones. 2013 Nov;18(6):801-8. (PMID: 23580156)
Trends Biochem Sci. 2019 Feb;44(2):153-166. (PMID: 30473428)
Aging (Albany NY). 2020 Nov 5;12(22):22582-22598. (PMID: 33159015)
Brief Bioinform. 2016 Jan;17(1):106-16. (PMID: 26041786)
Cancer Res. 2019 Sep 15;79(18):4557-4566. (PMID: 31350295)
J Cell Mol Med. 2019 Aug;23(8):4854-4865. (PMID: 31210425)
Radiol Oncol. 2020 May 2;54(2):135-143. (PMID: 32374292)
J Hematol Oncol. 2011 Sep 09;4:35. (PMID: 21906310)
Am Fam Physician. 2017 Oct 15;96(8):507-514. (PMID: 29094888)
OMICS. 2012 May;16(5):284-7. (PMID: 22455463)
Arch Esp Urol. 2018 May;71(4):349-357. (PMID: 29745924)
J Cell Biol. 2021 Feb 1;220(2):. (PMID: 33464299)
Cell Death Discov. 2021 Oct 5;7(1):278. (PMID: 34611133)
Medicina (Kaunas). 2021 Jul 24;57(8):. (PMID: 34440955)
Cell. 2021 Oct 14;184(21):5309-5337. (PMID: 34624224)
Oncoimmunology. 2015 Aug 12;5(2):e1069938. (PMID: 27057433)
Bioengineered. 2022 May;13(5):13986-13999. (PMID: 35758021)
Urol Oncol. 2021 Oct;39(10):642-663. (PMID: 34167873)
CA Cancer J Clin. 2020 Sep;70(5):404-423. (PMID: 32767764)
J Thorac Dis. 2018 Aug;10(8):4689-4693. (PMID: 30233840)
Mol Oncol. 2020 Dec;14(12):2994-3006. (PMID: 33179413)
Int J Mol Sci. 2022 Apr 01;23(7):. (PMID: 35409302)
Cell Death Dis. 2021 Nov 2;12(11):1043. (PMID: 34728613)
Mol Cancer. 2010 Jan 08;9:3. (PMID: 20059769)
J Clin Med. 2021 Dec 30;11(1):. (PMID: 35011943)
Int Immunopharmacol. 2020 Jul;84:106600. (PMID: 32417654)

SKJP＿220202675 Science and Technology Plan of Jiangxi Health Commission

Keywords: Bladder cancer; Immunogenic cell death; Nomogram; TCGA; Tumor Immune Microenvironment; lncRNAs

0 (RNA, Long Noncoding)
0 (Biomarkers, Tumor)

Date Created: 20240607 Date Completed: 20240607 Latest Revision: 20240610

20240611

PMC11161581

10.1038/s41598-024-63852-9

38849410